Solid-state mRNA vaccines hold 100% bioactivity at 37 °C in animal work
Solid-state mRNA vaccine formulations kept 100% bioactivity after more than 2 months at 37 °C, a Nature Biotechnology paper reports. The framework behind it, AGENT, couples high-throughput experiments with Bayesian optimization and finished in six iterations within 1 month. It stabilized two lipid nanoparticle types representative of Moderna (SM-102-based) and Pfizer-BioNTech (ALC-0315-based) compositions. In rodents and non-human primates, the vaccines induced antigen-specific immune responses non-inferior to freshly prepared soluble vaccines delivered intramuscularly.
Ultra-cold storage limits how far mRNA vaccines can be shipped. If the animal results hold in people, that constraint could ease.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].